Specific markers for metabolic syndrome

A metabolic syndrome and marker technology, which is applied in metabolic diseases, compound screening, drug combination, etc., can solve the problems of inapplicable routine screening, inapplicability, and high cost

Inactive Publication Date: 2005-05-25
F HOFFMANN LA ROCHE & CO AG
View PDF10 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These sophisticated techniques provide detailed determination of visceral adipose tissue levels, but are not suitable for routine means of comprehensive measurement of the community for healthcare purposes
Also, the costs associated with MRI and CT scans are quite high and therefore not suitable for routine screening

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Specific markers for metabolic syndrome
  • Specific markers for metabolic syndrome
  • Specific markers for metabolic syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0074] Total RNA was extracted using Ultraspec_RNA (Biotecx, Houston, TX) according to the manufacturer's protocol and treated with DNase for purification using the RNeasy Mini kit (Qiagen, Valencia, CA). Using T7-T24 primers, via SuperScript TM Double-stranded cDNA synthesis kit (LifeTechnology, Rockville, MD) synthesized double-stranded cDNA from 10 μg of total RNA. Double-stranded cDNA products were purified by phenol / chloroform / isoamyl alcohol extraction using phase-locked gels (Eppendorf, Westbury, NY). Using in vitro transcription (IVT) MEGAscript TM The double-stranded cDNA was further converted into cRNA by the T7 kit (Ambion, Austin, TX) and labeled with biotinyl nucleotide 1. In vitro transcripts were purified using the RNeasy Mini kit (Qiagen, Valencia, CA) and fragmented as described (Wodicka L, Dong H, Mittmann M, Ho MH, Lockhart DJ. Genome-wide expression monitoring in Saccharomyces cerevisiae. Nat Biotechnol 1997; 15:1359-67). Hybridization of fragmented in...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides a polypeptide predominantly expressed in visceral adipose tissue, which can be used as a marker for measuring the level of visceral adipose tissue in a patient. The present invention also provides methods of measuring visceral adipose tissue levels by obtaining a biological sample and detecting and / or measuring an increase in one or more polypeptides as disclosed herein. Screening methods for agonists and antagonists involving specific polypeptides disclosed herein are provided. Antibodies can be raised against these polypeptide markers for detection and / or treatment of metabolic syndrome involving co-morbidities.

Description

Background technique [0001] In both men and women, visceral adipose tissue accumulation is associated with an increased risk of developing non-insulin-dependent diabetes mellitus, myocardial infarction, stroke, and other arteriosclerotic diseases and their associated risk factors, including insulin resistance, elevated High blood lipids, glucose and high blood pressure. The clustering of these risk factors has been denoted as "metabolic syndrome", also known as "syndrome X", "insulin resistance syndrome" or "lethal tetralogy". The syndrome is also characterized by one or more endocrine disorders and is therefore also referred to as "neuro-endocrine syndrome" (Marin, P. Neuroendocrine News, 21(3) 1996, 2). These disturbances include low serum levels of sex hormones (testosterone in men and estrogen in women), signs of a lowering effect of growth hormone, and excessive secretion of cortisol. The latter has been shown clinically as a major causative process in the development o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/50A61K31/16A61K38/00A61K38/16A61K38/17A61K39/395A61K49/00A61P3/04A61P3/06A61P3/10A61P9/10A61P9/12C07K14/47C07K16/18C12N15/09C12Q1/68G01N33/15G01N33/68
CPCA61K31/16A61K38/1709A61K49/0004A61P3/04A61P3/06A61P3/10A61P9/00A61P9/10A61P9/12C12Q1/6883C12Q1/6888C12Q2600/158G01N33/6893G01N2500/00
Inventor 雅雷马·彼得·科汉詹姆斯·安德鲁·罗辛斯基
Owner F HOFFMANN LA ROCHE & CO AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap